Compounds > bis(2-ethylhexyl) 2,3,4,5-tetrabromophthalate
Page last updated: 2024-11-07

bis(2-ethylhexyl) 2,3,4,5-tetrabromophthalate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bis(2-ethylhexyl) 2,3,4,5-tetrabromophthalate: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID117291
CHEMBL ID3188536
SCHEMBL ID2729914
MeSH IDM0578955

Synonyms (44)

Synonym
bis(2-ethylhexyl) 3,4,5,6-tetrabromophthalate
1,2-benzenedicarboxylic acid, 3,4,5,6-tetrabromo-, bis(2-ethylhexyl) ester
26040-51-7
bis(2-ethylhexyl) tetrabromophthalate
tbph
pyronil 45
dp 45
di(2-ethylhexyl) tetrabromophthalate
bis(2-ethylhexyl) 3,4,5,6-tetrabromobenzene-1,2-dicarboxylate
cas-26040-51-7
dtxcid507887
dtxsid7027887 ,
tox21_302404
NCGC00255235-01
ec 247-426-5
unii-413m0n3v1g
1,2-benzenedicarboxylic acid, 3,4,5,6-tetrabromo-, 1,2-bis(2-ethylhexyl) ester
phthalic acid, tetrabromo-, bis(2-ethylhexyl) ester
di(2-ethylhexyl)tetrabromophthalate
einecs 247-426-5
phthalic acid, tetrabromo-, di(2-ethylhexyl) ester
bis(2-ethylhexyl) 2,3,4,5-tetrabromophthalate
413m0n3v1g ,
bis(2-ethyhexyl) tetrabromophthalate
hsdb 8216
AKOS016009450
FT-0674243
S11887
SCHEMBL2729914
bis(2-ethyl-1-hexyl) tetrabromophthalate
UUEDINPOVKWVAZ-UHFFFAOYSA-N
CS-W019373
W-110648
frp 45
CHEMBL3188536
c24h34br4o4
mfcd01941091
bis(2-ethylhexyl)-3,4,5,6-tetrabromophthalate
bis(2-ethylhexyl)3,4,5,6-tetrabromophthalate
di-2-ethylhexyl tetrabromo phthalate
DS-5244
Q19931407
A877383
bis(2-ethylhexyl) 3,4,5,6-tetrabromophthalate 100 microg/ml in hexane

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Mono-(2-ethyhexyl) tetrabromophthalate (TBMEHP) is a potentially toxic metabolite."( Rodent thyroid, liver, and fetal testis toxicity of the monoester metabolite of bis-(2-ethylhexyl) tetrabromophthalate (tbph), a novel brominated flame retardant present in indoor dust.
Boekelheide, K; Butt, CM; Dere, E; Hall, SJ; McClean, MD; McDonnell, EV; Roberts, SC; Schlezinger, JJ; Springer, C; Stapleton, HM; Watkins, DJ; Webster, TF, 2012)		0.38

Bioavailability

ExcerptReferenceRelevance
" Induction of CYP3A4 might cause undesired drug-drug interactions, lower bioavailability of pharmaceutical drugs, higher formation of reactive toxic metabolites, or enhanced elimination of endogenous hormones, such as T3/T4, to lead to endocrine disruption."( New brominated flame retardants and their metabolites as activators of the pregnane X receptor.
Carino, A; Distrutti, E; Fiorucci, S; Gramec Skledar, D; Peterlin Mašič, L; Tomašič, T, 2016)		0.43

Dosage Studied

ExcerptRelevanceReference
" Using authentic standards and mass spectrometry, we positively identified and quantified 2,3,4,5-tetrabromo benzoic acid (TBBA) and 2,3,4,5-tetrabromo phthalic acid (TBPA) in 24-h urine samples collected 1 day after dosing the rats and in serum at necropsy, 2 days post-exposure."( Quantification of tetrabromo benzoic acid and tetrabromo phthalic acid in rats exposed to the flame retardant Uniplex FPR-45.
Calafat, AM; Furr, J; Gray, LE; Hilton, D; Preau, JL; Silva, MJ; Ye, X, 2016)		0.43
" Transcriptomic analysis revealed a dose-response in the expression of genes associated with a surprisingly limited number of biological pathways, but included the aryl hydrocarbon receptor signal transduction pathway, which is known to respond to several toxicologically-important chemical classes."( Characterization of the Fundulus heteroclitus embryo transcriptional response and development of a gene expression-based fingerprint of exposure for the alternative flame retardant, TBPH (bis (2-ethylhexyl)-tetrabromophthalate).
Bencic, DC; Biales, AD; Burkhard, L; Clark, BW; Flick, RL; Huang, W; Lahren, T; Nacci, DE, 2019)		0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency7.93930.006038.004119,952.5996AID1159521; AID1159523
AR proteinHomo sapiens (human)Potency31.09640.000221.22318,912.5098AID1259243; AID1259247; AID1259381; AID743040; AID743042; AID743054; AID743063
progesterone receptorHomo sapiens (human)Potency42.23600.000417.946075.1148AID1346784; AID1347036
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency34.84420.000214.376460.0339AID720691; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency9.29880.003041.611522,387.1992AID1159552; AID1159555
pregnane X nuclear receptorHomo sapiens (human)Potency16.81450.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.37970.000229.305416,493.5996AID743075
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency21.16820.001723.839378.1014AID743083
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency30.161319.739145.978464.9432AID1159509
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (11.11)29.6817
2010's14 (77.78)24.3611
2020's2 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.51 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index5.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
phencyclidine
Phencyclidine: A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.. phencyclidine : A member of the class of piperidines that is piperidine in which the nitrogen is substituted with a 1-phenylcyclohexyl group. Formerly used as an anaesthetic agent, it exhibits both hallucinogenic and neurotoxic effects.		3.0140benzenes;
piperidines		anaesthetic;
neurotoxin;
NMDA receptor antagonist;
psychotropic drug
tetrabromobisphenol a
tetrabromobisphenol A: a brominated flame retardant. 3,3',5,5'-tetrabromobisphenol A : A bromobisphenol that is 4,4'-methanediyldiphenol in which the methylene hydrogens are replaced by two methyl groups and the phenyl rings are substituted by bromo groups at positions 2, 2', 6 and 6'. It is a brominated flame retardant.		2.110brominated flame retardant;
bromobisphenol
dechlorane plus
dechlorane plus: a flame retardant; structure in first source		2.0710
1,2-bis(2,4,6-tribromophenoxy)ethane
1,2-bis(2,4,6-tribromophenoxy)ethane: structure given in first source		2.5120
curcumin
Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.		2.3110aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger
decabromodiphenyl ethane
decabromodiphenyl ethane: structure in first source		2.1110
2-ethylhexyl 2,3,4,5-tetrabromobenzoate
2-ethylhexyl 2,3,4,5-tetrabromobenzoate: structure in first source		3.6990
ConditionIndicatedRelationship StrengthStudiesTrials
Acute Liver Injury, Drug-Induced
[description not available]		02.3110
Chemical and Drug Induced Liver Injury
A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.		02.3110
Obesity
A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).		02.3110
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		02.0710